Latest Breaking News On - Obseva announces united kingdom - Page 1 : comparemela.com

Investegate announcements from ObsEva SA, ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

United statesUnited kingdomGreat britainShauna dillonKatja buhrerBrian ocallaghanExchange commissionEuropean commissionHealthcare products regulatory agencySwiss exchangeObseva announces united kingdomUnited kingdom medicinesBriano callaghanAbout yseltyNasdaq global select marketCentral research laboratories